Ostarine (MK-2866): The Most Studied SARM Ever Developed

Verdict

What Is Ostarine?

Ostarine is a selective androgen receptor modulator (SARM). In plain terms, it is a synthetic compound designed to activate the body's muscle-building receptors while avoiding the receptors in tissues where androgen activity causes problems. It was developed by GTx, Inc. in Memphis, Tennessee, with James Dalton as lead researcher.^[4]

The concept behind SARMs is straightforward. Testosterone activates androgen receptors everywhere — muscle, bone, prostate, skin, scalp. A SARM, in theory, activates those receptors selectively — turning on the effects in muscle and bone while turning them down in everything else.^[5]

Ostarine is chemically unrelated to testosterone. It is not a steroid. It does not convert to estrogen. It does not convert to DHT. It is taken orally, has a half-life of roughly 24 hours, and was designed for once-daily dosing.

The compound has been known by several code names: GTx-024, MK-2866, S-22, and the generic name enobosarm. It holds the distinction of being the only SARM to reach Phase III clinical trials — and the only SARM to fail them.

Mechanism of Action

To understand ostarine, one distinction matters more than anything else: tissue-selective activation and non-suppressive activation are not the same thing. A compound can be selective about where it works while still shutting down natural hormone production.

graph TD
 A["Ostarine Ingested
(Oral, ~24-hr Half-Life)"] --> B["Enters Bloodstream
Distributes to Tissues"]
 B --> C["Binds Androgen Receptor
(Partial Agonist)"]
 C --> D["Skeletal Muscle
Moderate Protein Synthesis
Nitrogen Retention (+)"]
 C --> E["Bone Tissue
Moderate Anabolic Signal (+)"]
 C --> F["Prostate
REDUCED Androgenic Signal
(Tissue Selectivity)"]
 C --> G["Sebaceous Glands
REDUCED Activity
(Less Acne vs Testosterone)"]
 C --> H["Hypothalamus / Pituitary
Negative Feedback Detected"]
 H --> I["LH and FSH
DECREASED"]
 I --> J["Endogenous Testosterone
DECREASED (Suppression)"]

 style A fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style B fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style C fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style D fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style E fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style F fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style G fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style H fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style I fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style J fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 

Clinical Research — Peer-Reviewed Evidence

Ostarine has the strongest clinical evidence base of any SARM in existence. No other compound in this class comes close. But that distinction cuts both ways — because even the best SARM data tells a story of modest effects and a failed attempt at FDA approval.

Phase II — The Data That Built the Reputation

Dalton et al. 2011 — The Pivotal Elderly Study

This is the study that launched the ostarine narrative. A 12-week trial. 120 healthy elderly men and postmenopausal women. Randomized, double-blind, placebo-controlled. Four dose groups: 0.1 mg, 0.3 mg, 1 mg, and 3 mg daily.^[1]

At 3 mg, the results were clear. Subjects gained an average of +1.3 kg lean body mass versus placebo, measured by DEXA scan. Statistically significant. Stair climb power also improved. Higher doses produced greater effects — a clean dose-response curve.

Side effects were minimal. No serious adverse events at any dose. Testosterone declined in a dose-dependent pattern, but at 3 mg, values stayed within the normal range for most subjects. PSA (a prostate marker) did not increase.

This is the foundation of the “mildest SARM” reputation. At these doses, the data supports that label. The problem is what happened next — and where the internet stopped reading. Research-Validated — Phase II RCT

Dobs et al. 2013 — Cancer Cachexia Phase II

Ostarine was never designed for bodybuilding. Its intended purpose was preventing muscle wasting in cancer patients. Cachexia — the severe muscle loss that accompanies advanced cancer — weakens patients to the point where they cannot tolerate chemotherapy. Many die from weakness, not the cancer itself.

Dobs et al. enrolled 159 lung cancer patients receiving chemotherapy. Doses of 1 mg and 3 mg were given for 16 weeks.^[2]

The 3 mg group preserved significantly more lean body mass than placebo. Physical function results were mixed. But the data was strong enough to justify the biggest bet in SARM history: Phase III clinical trials. Research-Validated — Phase II RCT

Phase III — The Collapse

The POWER 1 and POWER 2 trials were the largest SARM clinical trials ever conducted. Hundreds of lung cancer cachexia patients. Two co-primary endpoints that both had to succeed: lean body mass preservation and stair climb power improvement.^[3]

Ostarine met the lean body mass endpoint. It preserved muscle mass in cancer patients undergoing chemotherapy.

Ostarine failed the stair climb power endpoint. Patients kept the weight on their bodies but could not climb stairs any faster. The muscle mass did not translate to functional strength.

The FDA requires both co-primary endpoints to succeed. One out of two is a failure. This result killed enobosarm's path to approval. GTx's stock collapsed. The company was restructured and acquired by Oncternal Therapeutics in 2019.

graph LR
 A["~2007
Phase I
Safety Established"] --> B["2011
Dalton Phase II
+1.3 kg Lean Mass
at 3 mg (Elderly)"]
 B --> C["2013
Dobs Phase II
Cancer Cachexia
Lean Mass Preserved"]
 C --> D["2013-2016
POWER Trials
Phase III
Largest SARM Trials"]
 D --> E["2016
PHASE III FAILED
Stair Climb Endpoint
NOT Met"]
 E --> F["2017-2019
GTx Restructured
Oncternal Acquisition"]
 F --> G["2026
No FDA Approval
No Active Development"]

 style A fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style B fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style C fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style D fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style E fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style F fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style G fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 

HPTA Suppression — What the Trials Actually Measured

Dalton 2011 provides the only clinical-grade suppression data for ostarine. Here is what happened at 1–3 mg/day over 12 weeks:^[1]

• Testosterone decreased in a dose-dependent pattern — higher doses, more suppression
• At 3 mg: The decline was statistically significant, but values stayed in the normal range for most subjects
• LH and FSH dropped as well — confirming the brain's hormonal control system was being suppressed
• Recovery happened on its own. Testosterone returned to baseline during the washout period with no PCT

This is solid, validated data. At clinical doses, ostarine genuinely earns its reputation as moderate.

But here is the gap that defines this compound's entire risk profile:

Body Composition — Lean Mass vs. Actual Muscle

The Phase II trials measured lean body mass using DEXA scans. DEXA measures everything that is not fat or bone — muscle tissue, water, glycogen, organ tissue. It does not measure actual muscle fiber growth.

A +1.3 kg lean mass increase over 12 weeks at 3 mg is real but modest. For perspective: creatine loading produces roughly 1–2 kg of lean mass increase (largely water and glycogen) within weeks. No study has ever biopsied ostarine subjects to measure actual muscle fiber growth.

The Phase III result drives this point home. Lean mass was preserved, but patients could not climb stairs any better. If the lean mass gain were actual contractile muscle, functional improvement would be expected. The stair climb failure raises a direct question: what exactly did the DEXA scan measure?

Common Questions — Dosing, Safety, Comparisons

Dosing in the Clinical Literature

The published clinical trials administered the following doses:^[1],[2],[3]

• Phase II: 0.1 mg, 0.3 mg, 1 mg, and 3 mg daily for 12–16 weeks
• Phase III: 3 mg daily (selected based on Phase II dose-response data)
• Half-life: ~24 hours, supporting once-daily oral dosing

Community doses of 10–25 mg/day are 5–25x higher than the highest clinical dose. No published clinical data exists at these levels. Community cycle lengths of 6–12 weeks fall within or exceed Phase II durations. The longest published trial ran 16 weeks.

Ostarine vs. Other SARMs

A key cross-reference: Basaria et al. showed that LGD-4033 at just 1 mg/day for 21 days produced significant hormonal suppression — total testosterone dropped substantially, and free testosterone fell by 40–50%.^[7] This matters because it confirms a pattern across the entire SARM class. Even at clinical doses, these compounds suppress natural testosterone production. The difference between SARMs is degree, not whether suppression happens.

Ostarine vs. Low-Dose Testosterone

This is the comparison most SARM content avoids. It deserves a direct look.

Low-dose testosterone (100–200 mg/week) fully activates androgen receptors in all tissues. Its effects are mapped by 60+ years of data. Suppression is complete but expected, and recovery protocols are well-documented.

Ostarine at community doses delivers a partial signal with tissue selectivity that has never been measured at those doses. The muscle-building effect is weaker. The suppression is still real. And the safety profile at community doses does not exist in any published literature.

The perceived advantage of ostarine — oral dosing, no estrogen, no DHT — comes at the cost of a weaker anabolic signal while still shutting down natural production. One position observed among practitioners: for physique enhancement, SARMs occupy an unfavorable spot on the risk-to-reward spectrum compared to well-managed low-dose testosterone. Expert-Discussed

Risk Profile Analysis

Risk 1: HPTA Suppression (Primary Concern at Community Doses)

Severity: Moderate-High (dose-dependent)

Dalton et al. confirmed dose-dependent testosterone suppression at 1–3 mg over 12 weeks. At those doses, testosterone stayed in the normal range and recovered on its own during the washout period.^[1]

At community doses (10–25 mg/day for 8–12 weeks), how severe the suppression gets and how long recovery takes are both unknown. No published data covers this range. The Dalton data cannot be stretched to fit — suppression may accelerate sharply at higher doses rather than scaling proportionally.

No clinical trial has ever tested PCT after an ostarine cycle. Every community PCT protocol is an extrapolation, not evidence. The PCT guide covers the pharmacological rationale in detail. Research-Validated at Clinical Doses / Data Gap at Community Doses

Risk 2: Lipid Changes

Severity: Low-Moderate

Dalton et al. observed dose-dependent HDL ("good cholesterol") suppression at clinical doses. At 3 mg, the drop was statistically significant but clinically modest. At community doses, the degree of lipid disruption is unmeasured.^[1]

Because ostarine does not convert to estrogen, the heart does not get estrogen's protective effects. This is the same concern that applies to non-aromatizing anabolic steroids. Research-Validated

Risk 3: Hepatotoxicity

Severity: Low

Clinical trials showed no significant liver enzyme elevations at 1–3 mg over 12–16 weeks. Ostarine lacks the 17-alpha-alkylation that makes many oral steroids liver-toxic, and no published case reports link ostarine to liver injury. By contrast, RAD-140 has documented liver toxicity cases.^[8]

That said, liver safety at community doses (5–25x higher than clinical) has not been established by any published data. Research-Validated at Clinical Doses

Risk 4: Product Contamination and Counterfeit Risk

Severity: Moderate

Ostarine is sold through research chemical vendors with zero pharmaceutical quality control. Independent analyses of these products have found wrong doses, contaminants, and outright label fraud. WADA has documented ostarine showing up in supplements sold as "natural" — either through manufacturing contamination or deliberate spiking.^[9]

Multiple athletes have faced anti-doping sanctions while claiming unintentional exposure. Third-party testing (HPLC/mass spectrometry) is the only reliable way to verify what is actually in a product. Research-Validated — Analytical Studies

Risk 5: Unknown Long-Term Effects

Severity: Unknown

The longest published trial ran 16 weeks. No published data covers chronic ostarine use spanning months or years. What happens to bone density, cardiovascular health, reproductive function, and cancer risk with repeated community-dose cycles over time is entirely unknown. Data Gap

graph LR
 subgraph Clinical["CLINICAL DATA (1-3 mg/day, 12-16 wk)"]
 A1["Testosterone:
Moderate Decline
Stayed in Normal Range"]
 A2["LH/FSH:
Moderate Suppression"]
 A3["Recovery:
Spontaneous, No PCT
Within Washout Period"]
 A4["Evidence Tier:
RESEARCH-VALIDATED"]
 end

 subgraph Community["COMMUNITY PRACTICE (10-25 mg/day, 8-12 wk)"]
 B1["Testosterone:
Unknown Magnitude
of Suppression"]
 B2["LH/FSH:
Unknown"]
 B3["Recovery:
Unknown Timeline"]
 B4["Evidence Tier:
NO CLINICAL DATA EXISTS"]
 end

 style A1 fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style A2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style A3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style A4 fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style B1 fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style B2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style B3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style B4 fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 

Evidence Synthesis

What the data supports:

• Modest lean body mass increase at clinical doses — +1.3 kg at 3 mg/day over 12 weeks in elderly subjects
• Dose-dependent hormonal suppression with spontaneous recovery at 1–3 mg — no PCT was needed at clinical doses
• Partial tissue selectivity — prostate activity (PSA) stayed stable, androgenic side effects were reduced in non-target tissues
• Clean safety profile at clinical doses — no serious adverse events, no meaningful liver toxicity

What the data contradicts:

• Phase III failure — lean mass preservation did not translate to functional improvement. Patients could not climb stairs better despite keeping muscle mass. That negative finding matters.
• The “safe oral steroid alternative” narrative — ostarine still suppresses natural testosterone, still worsens cholesterol, and still carries unknown risks at community doses. “Fewer known side effects” at unstudied doses is not the same as proven safe.

Where the data does not exist:

• Zero clinical data at community doses (10–25 mg/day). Suppression severity, efficacy, and safety at these doses are entirely extrapolated.
• No long-term data beyond 16 weeks in any population
• No muscle biopsy data — actual fiber hypertrophy is unmeasured
• No PCT data — no trial has ever tested SERM-based recovery after ostarine

The real question is not “Does ostarine work?” It does — modestly, at clinical doses. The real question is whether it works well enough to justify the risk compared to established alternatives like testosterone, which has vastly more safety data and substantially greater muscle-building potency.

quadrantChart
 title SARM vs AAS Risk-Reward Positioning
 x-axis Low HPTA Suppression --> Complete HPTA Suppression
 y-axis Low Anabolic Potency --> High Anabolic Potency
 quadrant-1 High Anabolic + High Suppression
 quadrant-2 High Anabolic + Low Suppression
 quadrant-3 Low Anabolic + Low Suppression
 quadrant-4 Low Anabolic + High Suppression
 Ostarine 3mg Clinical: [0.35, 0.20]
 LGD-4033 1mg Clinical: [0.45, 0.35]
 Low-Dose Testosterone: [0.80, 0.75]
 Full AAS Cycle: [0.90, 0.95]
 

For Physique Enhancement

The muscle-building potential of ostarine at clinical doses (3 mg) is modest. A +1.3 kg lean body mass gain over 12 weeks in elderly subjects does not compare to even low-dose testosterone. And the Phase III failure confirmed that the lean mass gained did not translate to functional strength — a finding that directly applies to anyone using ostarine for performance.^[1],[3]

The enhancement community uses ostarine at 5–25x clinical doses, assuming proportional benefit. That assumption has no clinical support. SARMs may plateau in their muscle-building effects, produce diminishing returns, or simply increase suppression without proportionally increasing results.

No aromatization means no estrogen-driven water retention. But it also means no estrogen-driven muscle growth. Estrogen contributes to muscle building through the GH/IGF-1 axis. A compound that cannot convert to estrogen loses that pathway entirely.

Hormonal suppression at community doses means recovery is a real concern. The perceived advantage of avoiding injections comes at the cost of still shutting down natural testosterone while providing a weaker muscle-building signal.

One position observed among practitioners: for physique goals, the risk-to-reward ratio of SARMs is unfavorable compared to well-managed low-dose testosterone. The SARM still suppresses the hormonal axis. It still requires PCT consideration. But it delivers substantially less result. Expert-Discussed

Oral convenience is the primary driver of ostarine's popularity. The oral-only cycles article addresses this same principle: convenience does not equal superiority. Related reading: first cycle guide, enclomiphene, PCT guide.

For Cognitive Enhancement

No published data exists on cognitive effects of ostarine in humans. Androgen receptor activity has theoretical brain-protective properties seen in animal studies, but nobody has tested ostarine specifically as a cognitive enhancer.

If someone reports sharper thinking during ostarine use, the likely explanations are improved body composition, mood changes, or placebo — not a direct brain-enhancing mechanism. No evidence-based cognitive claim can be made for this compound.

For nootropic options backed by actual human data, the nootropic focus protocol covers compounds with published clinical evidence for cognitive performance. No Clinical Data

Conclusions & Documented Dosing

Ostarine holds two distinctions: most clinically studied SARM ever developed, and the only SARM to fail Phase III clinical trials. Both facts matter equally in an honest assessment.

At clinical doses (1–3 mg/day), ostarine produced modest but real lean body mass increases, moderate hormonal suppression with spontaneous recovery, and a clean safety profile. At community doses (10–25 mg/day), zero published clinical data exists — not for efficacy, not for suppression severity, not for safety.

The “mildest SARM” label holds at 3 mg. It is unsubstantiated at 20 mg. That is the line between data and assumption.

References

1. Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153-161. PubMed
2. Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335-345. PubMed
3. Crawford J, Prado CM, Johnston MA, et al. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep. 2016;18(6):37. PubMed
4. Narayanan R, Coss CC, Dalton JT. Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465:134-142. PubMed
5. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12(3):232-240. PubMed
6. Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013;7(4):345-351. PubMed
7. Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87-95. PubMed
8. Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev. 2019;7(1):84-94. PubMed
9. Thevis M, Schanzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol. 2018;464:34-45. PubMed

Frequently Asked Questions